IFNA1 and melanoma: Moreover, tumor biopsies collected before treatment were evaluated for the expression of a panel of TAAs known to be highly expressed in > 80% of melanoma and used to assess the immunological efficacy of the treatment by IFN-ɣ ELISPOT assay.